Literature DB >> 3780766

The scintigraphic evaluation of myocardial infarction and regional ventricular performance using technetium-99m hexakis (t-butylisonitrile) technetium (I) (TBI): a new myocardial imaging agent.

S Campbell, B L Holman, J M Kirshenbaum, E M Antman, J Lister-James, A Davison, J Kozlowski, R J English, A G Jones.   

Abstract

Technetium-99m hexakis (t-butylisonitrile) technetium (I) (99mTc-TBI) is a new myocardial perfusion imaging agent. To determine its potential in the evaluation of myocardial infarction, 15 patients with suspected or confirmed acute infarction were studied by bedside imaging in the coronary care unit. Good-quality planar scintigrams in multiple projections were obtained in 13 patients. Gated perfusion studies were performed in 14 patients, and for comparison 13 of these were restudied 24-72 h later by standard gated equilibrium blood pool radionuclide ventriculography. Conventional and planar scintigraphic criteria for myocardial infarction (acute or old) agreed in 12 (92%) patients (k = 0.81, p less than 0.05). All the infarctions detected by scintigraphy were associated with electrocardiographic Q-waves. Localization of infarction by the electrocardiogram and scintigraphy exhibited moderate agreement (k = 0.49, p less than 0.1). Regional wall motion analysis by standard radionuclide ventriculography and gated 99mTc-TBI scintigraphy were in complete agreement for 25 (64%) of 39 left ventricular segments (k = 0.35, p less than 0.05). However, in 7 other segments, associated with areas of infarction, regional wall motion abnormalities were noted only on gated 99mTc-TBI scintigraphy. Therefore, 99mTc-TBI scintigraphy can readily provide data on regional myocardial perfusion and wall motion, permitting detection and localization of areas of myocardial infarction. The superior imaging properties, ready availability and low cost of 99mTc point to the considerable potential value of 99mTc-TBI in assessing patients with suspected or confirmed myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780766     DOI: 10.1007/bf00251973

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  24 in total

Review 1.  Thallium-201 myocardial scintigraphy.

Authors:  A S Iskandrian; A H Hakki
Journal:  Am Heart J       Date:  1985-01       Impact factor: 4.749

2.  Simultaneous detection of myocardial perfusion and wall motion abnormalities by cinematic 201Tl imaging.

Authors:  P O Alderson; H N Wagner; J J Gomez-Moeiras; T G Rehn; L C Becker; K H Douglas; H F Manspeaker; G R Schindledecker
Journal:  Radiology       Date:  1978-05       Impact factor: 11.105

3.  Value of early thallium-201 scintigraphy for predicting mortality in patients with acute myocardial infarction.

Authors:  K J Silverman; L C Becker; B H Bulkley; R D Burow; E D Mellits; C H Kallman; M L Weisfeldt
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

4.  Ejection fraction image: a noninvasive index of regional left ventricular wall motion.

Authors:  D E Maddox; B L Holman; J Wynne; J Idoine; J A Parker; R Uren; J M Neill; P F Cohn
Journal:  Am J Cardiol       Date:  1978-06       Impact factor: 2.778

5.  Serial measurements of left ventricular ejection fraction by radionuclide angiography early and late after myocardial infarction.

Authors:  H R Schelbert; H Henning; W L Ashburn; J W Verba; J S Karliner; R A O'Rourke
Journal:  Am J Cardiol       Date:  1976-10       Impact factor: 2.778

6.  Effect of infarct location on the in-hospital prognosis of patients with first transmural myocardial infarction.

Authors:  S Thanavaro; R E Kleiger; M A Province; J W Hubert; J P Miller; R J Krone; G C Oliver
Journal:  Circulation       Date:  1982-10       Impact factor: 29.690

7.  Estimation of infarct size by myocardial emission computed tomography with thallium-201 and its relation to creatine kinase-MB release after myocardial infarction in man.

Authors:  S Tamaki; H Nakajima; T Murakami; Y Yui; H Kambara; K Kadota; A Yoshida; C Kawai; N Tamaki; T Mukai; Y Ishii; K Torizuka
Journal:  Circulation       Date:  1982-11       Impact factor: 29.690

8.  Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.

Authors:  W B Kannel; R D Abbott
Journal:  N Engl J Med       Date:  1984-11-01       Impact factor: 91.245

9.  Value and limitations of thallium-201 scintigraphy in the acute phase of myocardial infarction.

Authors:  F J Wackers; E B Sokole; G Samson; J B Schoot; K I Lie; K L Liem; H J Wellens
Journal:  N Engl J Med       Date:  1976-07-01       Impact factor: 91.245

10.  Cationic Tc-99m complexes as potential myocardial imaging agents.

Authors:  E Deutsch; K A Glavan; V J Sodd; H Nishiyama; D L Ferguson; S J Lukes
Journal:  J Nucl Med       Date:  1981-10       Impact factor: 10.057

View more
  5 in total

1.  Same day injections of Tc-99m methoxy isobutyl isonitrile (hexamibi) for myocardial tomographic imaging: comparison between rest-stress and stress-rest injection sequences.

Authors:  R Taillefer; A Gagnon; L Laflamme; J Grégoire; J Léveillé; D C Phaneuf
Journal:  Eur J Nucl Med       Date:  1989

2.  99mTc-MIBI (RP-30) to define the extent of myocardial ischemia and evaluate ventricular function.

Authors:  M P Larock; R Cantineau; V Legrand; H Kulbertus; P Rigo
Journal:  Eur J Nucl Med       Date:  1990

3.  Myocardial perfusion imaging with 99mTc-methoxy-isobutyl-isonitrile (MIBI): comparison of short and long time intervals between rest and stress injections. Preliminary results.

Authors:  R Taillefer; L Laflamme; G Dupras; M Picard; D C Phaneuf; J Léveillé
Journal:  Eur J Nucl Med       Date:  1988

Review 4.  Myocardial scintigraphy--25 years after start.

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1988

5.  Clinical comparison between thallium-201 and Tc-99m-methoxy isobutyl isonitrile (hexamibi) myocardial perfusion imaging for detection of coronary artery disease.

Authors:  R Taillefer; R Lambert; G Dupras; J Grégoire; J Léveillé; R Essiambre; D C Phaneuf
Journal:  Eur J Nucl Med       Date:  1989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.